Narnatumab is a human monoclonal antibody designed for the treatment of cancer.[1] Clinical development was abandoned after phase I trials.[2][3]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | MST1R (aka RON) |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6454H10026N1754O2020S44 |
| Molar mass | 145922.10 g·mol−1 |
  (what is this?) (verify) | |
Narnatumab was developed by ImClone Systems.
References
edit- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab" (PDF). American Medical Association. Archived from the original (PDF) on 28 September 2012.
- ^ "Narnatumumab". AdisInsight. Springer Nature Switzerland AG. Retrieved 31 January 2017.
- ^ LoRusso PM, Gounder M, Jalal SI, André V, Kambhampati SR, Loizos N, et al. (August 2017). "Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors". Investigational New Drugs. 35 (4): 442–450. doi:10.1007/s10637-016-0413-0. PMC 5502198. PMID 28161886.442-450&rft.date=2017-08&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502198#id-name=PMC&rft_id=info:pmid/28161886&rft_id=info:doi/10.1007/s10637-016-0413-0&rft.aulast=LoRusso&rft.aufirst=PM&rft.au=Gounder, M&rft.au=Jalal, SI&rft.au=André, V&rft.au=Kambhampati, SR&rft.au=Loizos, N&rft.au=Hall, J&rft.au=Holzer, TR&rft.au=Nasir, A&rft.au=Cosaert, J&rft.au=Kauh, J&rft.au=Chiorean, EG&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502198&rfr_id=info:sid/en.wikipedia.org:Narnatumab" class="Z3988">
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |